Treatment and prognosis of pT1N0M0 Luminal B-like breast cancer
10.3781/j.issn.1000-7431.2018.33.258
- Author:
Shixia WANG
1
Author Information
1. Second Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Breast neoplasms;
Prognosis
- From:
Tumor
2018;38(7):689-696
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinicopathological characteristics, treatment and prognosis of Luminal B-like breast cancer in pT1N0M0 stage. Methods: The data of 300 patients with stage pT1N0M0 Luminal B-like breast cancer who underwent surgery in Tianjin Medical University Cancer Institute and Hospital from January 2010 to January 2013 were collected. The clinicopathological characteristics, treatment and prognosis were retrospectively analyzed by using the statistical methods such as χ2 test, univariate analysis, COX multivariate analysis, Kaplan-Meier and so on. Results: In 300 cases of breast cancer, there were 24 cases (8%) in pT1aN0M0 stage, 115 cases (38.3%) in pT1bN0M0 stage, and 161 cases (53.7%) in pT1cN0M0 stage. Intergroup analysis (χ2 test) showed that only histological grade was related to tumor size (P = 0.004). Univariate analysis showed that age, histological grade, human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 expression and chemotherapy had an effect on the five-year disease-free survival (DFS) of patients (all P < 0.05), and HER-2 was associated with five-year overall survival (OS) rate (P < 0.05). Multivariate analysis showed that histological grade (P = 0.048), chemotherapy (P = 0.046), HER-2 (P = 0.001) status and Ki-67 expression (P = 0.002) were independent factors of five-year DFS rate of the patients. The relationship between chemotherapy regimens and prognosis was further analyzed, and the results showed that five-year DFS rate and OS rate of the patients in pT1a-bN0M0 stage had no significant difference between taxane/anthracycline alone chemotherapy group and taxane combined with anthracycline group (both P > 0.05). For the patients in pT1cN0M0, the five-year DFS rate in taxane combined with anthracycline chemotherapy group was significantly higher than that in taxane/anthracycline alone chemotherapy group (P = 0.042), but the five-year OS rate was not significant different between the two groups (P = 0.711). Conclusion: Postoperative adjuvant chemotherapy can improve the prognosis of patients with stage pT1N0M0 Luminal B-like breast cancer. The patients in pT1a-bN0M0 stage may be given taxanes/anthraquinones chemotherapy for reducing overtreatment. For the patients in pT1cN0M0 stage, the prognosis will be better when the taxane combined with anthracycline chemotherapy is given.
